Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Screening for testicular cancer

Kenneth W Lin, MD, MPH
Section Editor
Joann G Elmore, MD, MPH
Deputy Editor
Judith A Melin, MA, MD, FACP


Testicular cancer accounts for only about 1 percent of cancers in men overall but is the most common malignancy in males between the ages of 15 and 35 years [1]. Most testicular cancers are germ cell tumors. The prognosis with treatment is generally excellent.

This topic will review issues related to screening for testicular cancer, including the lack of evidence that routine screening improves favorable outcomes for this disease.

The epidemiology, clinical manifestations, and treatment for testicular cancer are discussed separately.

(See "Epidemiology of and risk factors for testicular germ cell tumors".)

(See "Clinical manifestations, diagnosis, and staging of testicular germ cell tumors".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Oct 20, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.
  2. https://seer.cancer.gov/statfacts/html/testis.html (Accessed on May 27, 2017).
  3. Stevenson SM, Lowrance WT. Epidemiology and Diagnosis of Testis Cancer. Urol Clin North Am 2015; 42:269.
  4. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3:524.
  5. McGlynn KA, Devesa SS, Sigurdson AJ, et al. Trends in the incidence of testicular germ cell tumors in the United States. Cancer 2003; 97:63.
  6. Townsend JS, Richardson LC, German RR. Incidence of testicular cancer in the United States, 1999-2004. Am J Mens Health 2010; 4:353.
  7. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003; 170:5.
  8. National Cancer Institute. Testicular cancer treatment (PDQ) summary: health professional version. National Cancer Institute, Bethesda, MD 2011. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/testicular/HealthProfessional (Accessed on October 11, 2011).
  9. van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006; 42:820.
  10. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev 2011; :CD007853.
  11. Lin K, Sharangpani R. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153:396.
  12. US Preventive Services Task Force. U.S. Preventive Services Task Force. In: Guide to Clinical Preventive Services, 2nd ed, US Department of Health and Human Services, Washington, DC 1996. p.153.
  13. National Cancer Institute: PDQ® Testicular Cancer Screening. Bethesda, MD: National Cancer Institute. Date last modified 03/04/2016. Available at: . http://www.cancer.gov/types/testicular/hp/testicular-screening-pdq (Accessed on April 06, 2016).
  14. U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2011; 154:483.
  15. Mir MC, Pavan N, Gonzalgo ML. Current Clinical Applications of Testicular Cancer Biomarkers. Urol Clin North Am 2016; 43:119.
  16. Shaw J. Diagnosis and treatment of testicular cancer. Am Fam Physician 2008; 77:469.
  17. Lip SZ, Murchison LE, Cullis PS, et al. A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 2013; 98:20.
  18. Chan E, Wayne C, Nasr A, FRCSC for Canadian Association of Pediatric Surgeon Evidence-Based Resource. Ideal timing of orchiopexy: a systematic review. Pediatr Surg Int 2014; 30:87.
  19. Kolon TF, Herndon CD, Baker LA, et al. Evaluation and treatment of cryptorchidism: AUA guideline. J Urol 2014; 192:337.
  20. AAFP Clinical Preventive Service Recommendation http://www.aafp.org/patient-care/clinical-recommendations/all/testicular-cancer.html (Accessed on June 13, 2017).
  21. Bright Futures/American Academy of Pediatrics. Recommendations for Preventive Pediatric Health Care. February 2017 https://www.aap.org/en-us/professional-resources/practice-transformation/managing-patients/Pages/Periodicity-Schedule.aspx (Accessed on February 21, 2017).
  22. American Cancer Society: Can Testicular Cancer Be Found Early? https://www.cancer.org/cancer/testicular-cancer/detection-diagnosis-staging/detection.html (Accessed on June 13, 2017).
  23. http://uroweb.org/guideline/testicular-cancer/ (Accessed on June 08, 2017).